Prior authorization / coverage note — breath tests for IEI

Breath hydrogen and/or methane testing (CPT 91065) is included in the coding list but the policy explicitly states that use of a breath hydrogen and/or breath methane test to assess or diagnose idiopathic environmental intolerance (IEI) is not reimbursable.

• CPT 91065 is listed in the coding section but excluded when used to assess or diagnose IEI.
• Providers should confirm member benefits for any breath testing unrelated to IEI indications.

Prior authorization — laboratory‑developed tests (LDTs)

Laboratory-developed tests (LDTs) for IEI are performed in-house and are regulated under CLIA as high-complexity tests; the policy notes these tests are generally not FDA-cleared and may be subject to payer-specific prior authorization.

• LDTs are regulated by CMS as high-complexity tests under CLIA '88.
• LDTs are not approved or cleared by the FDA; clinical use does not require FDA clearance but coverage may be affected.

Coding update — removed CPT codes (prior auth impact not specified)

The policy documents a coding update removing CPT codes 83921 and 84600; no specific changes to prior authorization rules are specified in the extract.

• Removed CPT codes: 83921 and 84600 (coding update noted 02/06/26).
• No explicit prior authorization impacts described in the policy extract.

Clinical step approach — prioritize history, exam, and targeted testing

Before ordering broad proprietary panels for IEI, providers should prioritize a focused clinical evaluation — history, physical exam, baseline labs — and reserve targeted testing guided by symptoms rather than ordering broad, nonvalidated panels.

• Initial evaluation should include history, physical examination, and baseline laboratory tests (CBC, serum electrolytes, glucose, urinalysis).
• Further testing should be symptom-guided; avoid broad proprietary panels to evaluate IEI.

Preferred diagnostic sequence for SIBO — breath testing first

For suspected SIBO, guidelines recommend using noninvasive breath testing (glucose or lactulose hydrogen breath tests) to assess antibiotic‑responsive microbial colonization and to evaluate methane production in patients with constipation prior to more invasive testing.

• Breath testing is suggested to assess antibiotic‑responsive microbial colonization and to evaluate excessive methane excretion in association with constipation.
• Consider breath testing (glucose or lactulose) before invasive small bowel culture techniques which are not a satisfactory routine standard.

Recommended clinical evaluation documentation — history, exam, baseline labs

When evaluating suspected IEI, document a detailed history and physical exam and include baseline laboratory tests: complete blood count (CBC), serum electrolytes, glucose, and urinalysis as part of the initial assessment.

• Include occupational/environmental exposure history and consider psychiatric screening (eg, PHQ-9) as recommended.
• Use baseline labs (CBC, electrolytes, glucose, urinalysis) to guide further, symptom-directed testing.

Documentation for breath testing — record symptoms, prior evaluations, rationale

When ordering breath testing (eg, for SIBO or carbohydrate maldigestion), document the patient's clinical symptoms, prior evaluations (imaging/endoscopy), clinical rationale for testing, and any prior surgeries or conditions that predispose to SIBO.

• Document symptoms such as bloating, abdominal pain, diarrhea, gas and note prior luminal abdominal surgery or suspected motility disorders.
• Record rationale for breath testing and prior evaluations to support the indication for testing.

Documentation note — IEI testing not reimbursable; verify member benefits

The policy has been added to Routine Test Management clarifying that testing for idiopathic environmental intolerance (IEI) is not reimbursable; providers should consult the member benefit booklet or customer service for member‑specific coverage details before ordering.

• Explicit policy statement: In all circumstances, any type of testing for IEI is not reimbursable.
• Check member benefit booklet or contact member services to determine coverage for related services.

Denial risk — diagnostic testing for IEI not reimbursable

Ordering laboratory tests intended to confirm a diagnosis of idiopathic environmental intolerance (IEI) will not be reimbursed; providers risk denial of claims for such testing.

• The policy states: In all circumstances, laboratory tests designed to confirm the diagnosis of idiopathic environmental intolerance is not reimbursable.
• Do not submit claims for tests ordered solely to diagnose IEI.

Denial risk — toxin/chemical/metal profiling not reimbursable

Screening or profiling panels for volatile solvents, organic acids, organophosphates, phthalates, parabens, chlorinated pesticides, and metals using blood, serum, plasma, saliva, urine, stool, fingernails, or hair are not reimbursable and will be denied.

• Policy items explicitly exclude these analytes and specimen types from reimbursement when used for IEI or in asymptomatic individuals.
• Avoid ordering these profiling tests for the purpose of diagnosing IEI.

LDT regulatory note — CLIA high‑complexity; generally not FDA‑cleared

Laboratory‑developed tests (LDTs) used to evaluate IEI are CLIA‑regulated as high‑complexity tests and are generally not FDA‑cleared; lack of FDA clearance is noted in the policy and may influence coverage decisions.

• LDTs must be validated and are regulated under CLIA '88 as high‑complexity tests.
• The policy states no specific FDA‑cleared test for IEI was found; LDTs are not FDA‑approved or cleared.

Denial risk — all IEI testing excluded from reimbursement

The policy includes an explicit addition: in all circumstances, any type of testing for idiopathic environmental intolerance (IEI) is not reimbursable—claims for IEI testing will be denied.

• This is an explicit Routine Test Management policy statement added to the document.
• No clinical exceptions for IEI testing are listed in the extract.

Ordering requirements: start with clinical evaluation and symptom‑driven targeted testing

Appropriate ordering begins with a clinical evaluation (history, physical exam) and baseline labs; testing should be symptom‑driven and targeted rather than broad panel screening.

• Perform psychiatric screening and obtain occupational/environmental exposure history before extensive laboratory testing.

Ordering requirements: document symptoms and prior evaluations; limit breath testing to guideline‑supported symptomatic patients

When ordering breath tests, document the patient’s clinical symptoms and prior evaluations (imaging/endoscopy) and order breath testing only for symptomatic patients where guidelines support its use (eg, suspected motility disorder, prior surgery, or constipation with suspected methane production).

• Guidelines recommend breath testing in symptomatic patients and to evaluate methane in association with constipation.
• Ensure documentation explains how the test result will influence management.